↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

134 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
3 Acute myeloid leukemia 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
4 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Acute myeloid leukemia 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
6 Adherens junction 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
7 Adherens junction 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
8 Adherens junction 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
9 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
10 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
11 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
12 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
14 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
15 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
16 Alzheimer disease 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
17 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
18 Alzheimer disease 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
19 Alzheimer disease 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
20 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
21 AMPK signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
22 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
23 AMPK signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
24 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
25 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
26 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
27 Apelin signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
28 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
29 Apelin signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
30 Arachidonic acid metabolism 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
31 Autophagy - animal 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
32 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
33 Autophagy - animal 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
34 Autophagy - other 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
35 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
36 Autophagy - other 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
37 Axon guidance 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
38 Axon guidance 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
39 Axon guidance 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
40 Bacterial invasion of epithelial cells 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
41 beta-Alanine metabolism 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
42 Bile secretion 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
43 Bladder cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
44 Bladder cancer 💬
 1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
45 Bladder cancer 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
46 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
47 Breast cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
48 Breast cancer 💬
 2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
49 Breast cancer 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
50 Breast cancer 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
51 Breast cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
52 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
53 Breast cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
54 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
55 C-type lectin receptor signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
56 C-type lectin receptor signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
57 Calcium signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
58 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
59 Calcium signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
60 Calcium signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
61 Calcium signaling pathway 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
62 Calcium signaling pathway 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
63 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
64 cAMP signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
65 cAMP signaling pathway 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
66 cAMP signaling pathway 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
67 Cell cycle 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
68 Cell cycle 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
69 Cell cycle 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
70 Cellular senescence 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
71 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
72 Cellular senescence 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
73 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
74 Central carbon metabolism in cancer 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
75 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
76 Central carbon metabolism in cancer 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
77 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
78 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
79 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
80 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
81 Chemical carcinogenesis 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
82 Chemokine signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
83 Choline metabolism in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
84 Choline metabolism in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
85 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
86 Choline metabolism in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
87 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
88 Choline metabolism in cancer 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
89 Choline metabolism in cancer 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
90 Chronic myeloid leukemia 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
91 Chronic myeloid leukemia 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
92 Chronic myeloid leukemia 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
93 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
94 Colorectal cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
95 Colorectal cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
96 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
97 Colorectal cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
98 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
99 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
100 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
101 Cushing syndrome 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
102 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
103 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
104 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
105 EGFR tyrosine kinase inhibitor resistance 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
106 EGFR tyrosine kinase inhibitor resistance 💬
 5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
107 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
108 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
109 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
110 EGFR tyrosine kinase inhibitor resistance 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
111 EGFR tyrosine kinase inhibitor resistance 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
112 EGFR tyrosine kinase inhibitor resistance 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
113 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
114 Endocrine resistance 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
115 Endocrine resistance 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
116 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
117 Endocrine resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
118 Endocrine resistance 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
119 Endocytosis 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
120 Endocytosis 💬
 3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
121 Endocytosis 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
122 Endocytosis 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
123 Endocytosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
124 Endometrial cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
125 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
126 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
127 ErbB signaling pathway 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
128 ErbB signaling pathway 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
129 ErbB signaling pathway 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
130 ErbB signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
131 ErbB signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
132 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
133 ErbB signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
134 Estrogen signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
135 Estrogen signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
136 Fluid shear stress and atherosclerosis 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
137 Fluid shear stress and atherosclerosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
138 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
139 Focal adhesion 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
140 Focal adhesion 💬
 5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
141 Focal adhesion 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
142 Focal adhesion 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
143 Focal adhesion 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
144 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
145 FoxO signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
146 GABAergic synapse 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
147 GABAergic synapse 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
148 Gap junction 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
149 Gap junction 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
150 Gap junction 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
151 Gap junction 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
152 Gap junction 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
153 Gastric acid secretion 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
154 Gastric acid secretion 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
155 Gastric cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
156 Gastric cancer 💬
 1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
157 Gastric cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
158 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
159 Gastric cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
160 Glioma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
161 Glioma 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
162 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
163 Glioma 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
164 Glioma 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
165 Glioma 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
166 Glioma 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
167 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
168 GnRH signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
169 GnRH signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
170 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
171 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
172 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
173 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
174 Growth hormone synthesis, secretion and action 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
175 Hematopoietic cell lineage 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
176 Hematopoietic cell lineage 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
177 Hepatitis B 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
178 Hepatitis C 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
179 Hepatocellular carcinoma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
180 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
181 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
182 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
183 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
184 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
185 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
186 Herpes simplex virus 1 infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
187 HIF-1 signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
188 HIF-1 signaling pathway 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
189 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
190 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
191 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
192 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
193 Human cytomegalovirus infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
194 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
195 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
196 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
197 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
198 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
199 Human cytomegalovirus infection 💬
 1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
200 Human cytomegalovirus infection 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
201 Human cytomegalovirus infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
202 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
203 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
204 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
205 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
206 Human papillomavirus infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
207 Human papillomavirus infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
208 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
209 Human papillomavirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
210 Human papillomavirus infection 💬
 1件: PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
211 Human papillomavirus infection 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
212 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
213 Huntington disease 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
214 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
215 Huntington disease 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
216 IL-17 signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
217 Inflammatory mediator regulation of TRP channels 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
218 Insulin resistance 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
219 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
220 Insulin resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
221 Insulin signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
222 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
223 Insulin signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
224 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
225 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
226 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
227 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
228 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
229 JAK-STAT signaling pathway 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
230 JAK-STAT signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
231 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
232 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
233 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
234 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
235 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
236 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
237 Leishmaniasis 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
238 Longevity regulating pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
239 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
240 Longevity regulating pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
241 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
242 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
243 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
244 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
245 MAPK signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
246 MAPK signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
247 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
248 MAPK signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
249 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
250 Melanogenesis 💬
 1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
251 Melanogenesis 💬
 1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
252 Melanoma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
253 Melanoma 💬
 3件: FGFR1, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
254 Melanoma 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
255 Melanoma 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
256 Metabolic pathways 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
257 Metabolic pathways 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
258 Metabolic pathways 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
259 Metabolic pathways 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
260 MicroRNAs in cancer 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
261 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
262 MicroRNAs in cancer 💬
 2件: ABL1, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
263 MicroRNAs in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
264 MicroRNAs in cancer 💬
 3件: FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
265 MicroRNAs in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
266 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
267 MicroRNAs in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
268 MicroRNAs in cancer 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
269 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
270 Mitophagy - animal 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
271 mTOR signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
272 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
273 mTOR signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
274 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
275 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
276 Neuroactive ligand-receptor interaction 💬
 1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
277 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
278 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
279 Neurotrophin signaling pathway 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
280 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
281 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
282 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
283 Neutrophil extracellular trap formation 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
284 NF-kappa B signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
285 Non-small cell lung cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
286 Ovarian steroidogenesis 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
287 Ovarian steroidogenesis 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
288 Oxytocin signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
289 Oxytocin signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
290 Oxytocin signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
291 Pancreatic cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
292 Pancreatic cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
293 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
294 Pancreatic cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
295 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
296 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
297 Parathyroid hormone synthesis, secretion and action 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
298 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
299 Pathogenic Escherichia coli infection 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
300 Pathogenic Escherichia coli infection 💬
 2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
301 Pathways in cancer 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
302 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
303 Pathways in cancer 💬
 3件: ABL1, KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
304 Pathways in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
305 Pathways in cancer 💬
 6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
306 Pathways in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
307 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
308 Pathways in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
309 Pathways in cancer 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
310 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
311 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
312 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
313 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
314 Pathways of neurodegeneration - multiple diseases 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
315 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
316 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
317 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
318 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
319 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
320 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
321 Phospholipase D signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
322 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
323 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
324 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
325 Phospholipase D signaling pathway 💬
 2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
326 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
327 PI3K-Akt signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
328 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
329 PI3K-Akt signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
330 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
331 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
332 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
333 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
334 Platelet activation 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
335 Prolactin signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
336 Propanoate metabolism 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
337 Prostate cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
338 Prostate cancer 💬
 4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
339 Prostate cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
340 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
341 Prostate cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
342 Prostate cancer 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
343 Prostate cancer 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
344 Proteoglycans in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
345 Proteoglycans in cancer 💬
 2件: FGFR1, KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
346 Proteoglycans in cancer 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
347 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
348 Proteoglycans in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
349 Proteoglycans in cancer 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
350 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
351 Rap1 signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
352 Rap1 signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
353 Rap1 signaling pathway 💬
 2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
354 Rap1 signaling pathway 💬
 2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
355 Rap1 signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
356 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
357 Ras signaling pathway 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
358 Ras signaling pathway 💬
 3件: ABL1, KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
359 Ras signaling pathway 💬
 3件: ABL1, KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
360 Ras signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
361 Ras signaling pathway 💬
 8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
362 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
363 Regulation of actin cytoskeleton 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
364 Regulation of actin cytoskeleton 💬
 5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
365 Regulation of actin cytoskeleton 💬
 1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
366 Regulation of actin cytoskeleton 💬
 1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
367 Regulation of actin cytoskeleton 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
368 Regulation of lipolysis in adipocytes 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
369 Regulation of lipolysis in adipocytes 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
370 Relaxin signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
371 Relaxin signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
372 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
373 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
374 Renin secretion 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
375 Retrograde endocannabinoid signaling 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
376 Rheumatoid arthritis 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
377 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
378 Salivary secretion 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
379 Serotonergic synapse 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
380 Shigellosis 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
381 Shigellosis 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
382 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
383 Shigellosis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
384 Shigellosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
385 Signaling pathways regulating pluripotency of stem cells 💬
 3件: FGFR1, FGFR2, FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
386 Small cell lung cancer 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
387 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
388 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
389 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
390 Steroid hormone biosynthesis 💬
 1件: CYP19A1 💬 D00964 💬 Letrozole 2件: 81, 89 💬
391 Taurine and hypotaurine metabolism 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
392 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
393 Th17 cell differentiation 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
394 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
395 Th17 cell differentiation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
396 Thermogenesis 💬
 1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
397 Thermogenesis 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
398 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
399 Thermogenesis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
400 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
401 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
402 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
403 Thyroid hormone signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
404 Tight junction 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
405 TNF signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
406 Transcriptional misregulation in cancer 💬
 1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
407 Tuberculosis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
408 Type I diabetes mellitus 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
409 Type II diabetes mellitus 💬
 1件: CACNA1G 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
410 Type II diabetes mellitus 💬
 1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
411 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
412 Type II diabetes mellitus 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
413 Valine, leucine and isoleucine degradation 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
414 VEGF signaling pathway 💬
 1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
415 VEGF signaling pathway 💬
 1件: PTGS2 💬 D00567 💬 Celecoxib 9件:  2 ,  3 , 34, 46, 70, 89, 161, 171, 271 💬
416 VEGF signaling pathway 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
417 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
418 Viral carcinogenesis 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
419 Viral myocarditis 💬
 1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
420 Viral myocarditis 💬
 1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
421 Viral myocarditis 💬
 1件: ABL1 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬
422 Yersinia infection 💬
 1件: SRC 💬 D09664 💬 Saracatinib 3件:  6 , 89, 272 💬

先頭へ